POLYCYTHEMIA VERA

This study follows 200 adults with polycythemia vera (a blood cancer causing too many red blood cells) who are taking ropeginterferon alfa-2b in real-world German clinics. Researchers will track patients' symptom burden, how well the drug controls blood counts, and safety over th…

This study is testing whether adding a new drug called iadademstat to an existing treatment (ASTX727) works better for controlling advanced blood cancers. It will involve about 62 adults with specific aggressive forms of myeloproliferative neoplasms (MPNs) that have progressed. T…

This study is testing a modified, two-step stem cell transplant procedure designed to be safer. It aims to reduce deaths caused by the transplant treatment itself in patients with various blood cancers and disorders. The trial compares two gentler preparation methods using lower …

This study continues treatment for 400 people with rare blood cancers who are already benefiting from the drug bomedemstat in earlier trials. Its main goal is to collect long-term safety information and see how well the drug continues to control the disease over time. The study i…

This trial is testing whether a combination of chemotherapy and targeted drugs can better prepare patients with advanced blood cancers for a stem cell transplant. The goal is to control the aggressive cancer enough so patients can safely receive donor stem cells, which may offer …

This study is testing if an investigational drug called Givinostat works better than the current standard treatment, hydroxyurea, for adults with a high-risk form of a blood cancer called polycythemia vera. The goal is to see if Givinostat can more effectively control blood count…

This study follows 36 Italian patients with Polycythemia Vera, a chronic blood cancer, who previously responded well to the drug Ropeginterferon alfa-2b. Researchers will track these patients for several years to see if the treatment continues to control their disease safely and …

This large Phase 3 trial aims to prevent life-threatening blood clots in people with certain high-risk blood cancers. It will compare newer, more potent blood thinners (apixaban/rivaroxaban) against standard low-dose aspirin in over 1,300 patients. The goal is to see if the newer…

This study aims to find the best dose of N-Acetylcysteine (N-AC), a common supplement, to help reduce symptoms in people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It will enroll 27 adults with ET, PV, or MF who have significant symptom burden. The main g…

This study is testing whether a curcumin supplement, the active ingredient in turmeric, can reduce inflammation and improve symptoms in people with certain blood cell disorders. Researchers will compare the supplement to a placebo in 30 participants over 12 months. The main goals…

This study is testing whether the drug ruxolitinib can reduce the often severe symptoms experienced by people with low-risk essential thrombocythemia (ET) or polycythemia vera (PV). About 60 participants with significant symptom burdens will take the drug for at least 6 months to…

This study aims to learn how a specific type of immune cell, called a monocyte, behaves in people with certain blood cancers. Researchers will collect blood samples from 70 participants who have not yet started treatment for their condition. By analyzing these cells, they hope to…

This study aims to understand why some patients with a blood cancer called essential thrombocythemia (ET) later develop a related cancer called polycythemia vera (PV). Researchers will look back at the medical records of 678 patients to identify risk factors for this change and c…

This is a long-term observational study aiming to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. who have been diagnosed with an MPN for at least five years, collecting information from …